Descripción del proyecto
Un dispositivo para la toma de muestras de sangre en casa
Los pacientes de trasplante de riñón reciben fármacos inmunosupresores y deben controlar continuamente sus niveles a través de muestras de sangre para garantizar que se mantienen dentro de la ventana terapéutica. El proyecto ISACS, financiado con fondos europeos, realizó una evaluación de la viabilidad y desarrolló un plan de negocio para el uso de dispositivos para la toma de muestras de sangre en casa de Capitainer en el campo del control de fármacos terapéuticos para pacientes de trasplante de hígado y riñón. El sistema es portátil, rentable y fácil de utilizar, y la muestra se envía al hospital a través del correo ordinario. El sistema permite a los pacientes trasplantados evitar visitas frecuentes al hospital para realizar una extracción de sangre tradicional y asegura que se mantenga un control regular sobre su estado para evitar el rechazo de órganos.
Objetivo
Capitainer AB aims to develop a business plan for the broad-scale commercial launch of Capitainer-B – an innovative tool for quantitative blood microsampling. For kidney transplant patients, a new organ eliminates the need of frequent dialysis and improves the quality of life, but to prevent rejection of the new organ by the patient’s own immune system, lifelong treatment with immunosuppressive drugs is necessary. To ensure that the concentration of drugs remain within their therapeutic windows, drug levels are continuously measured through blood testing after transplantation: TDM - Therapeutic Drug Monitoring. Traditional phlebotomy at the hospital consumes substantial resources from the healthcare system and for patients, frequent visits to the hospital/test station is a source of inconvenience. As such, the development of an accurate “use-at-home” blood sampling tool that can alleviate this heavy burden is in great demand. Filling this market gap, Capitainer AB proposes Capitainer-B - a portable, cost effective and easy-to-use microsampling system which enables the patient to take a blood sample at home through a finger prick. The sample can be sent via regular mail to the laboratory for analysis. Our design philosophy was to create a reliable and easy to use tool for monitoring drug concentrations in blood, thereby reducing the risk of organ refusal. From the business perspective, Capitainer-B expands into the market space delineated by the variables of volume accuracy, patient proximity, mobility and low cost. The device has already attracted attention of one EU-based medical centre in Germany (Labor Dessau GmbH) which resulted in a research partnership and low scale sales. In this Phase 1 Project, Capitainer AB intends to prepare a multispectral market feasibility assessment for Capitainer-B. Furthermore, we plan to study the market capacity for the further Capitainer-B-type devices, aiming at providing a comprehensive blood testing platform.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
171 45 Solna
Suecia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.